Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Tumors are heterogeneous with varying response to chemotherapeutic agents. We hypothesize
that tumors that are sensitive to a particular chemotherapeutic agent have a distinctive
tumor protein profile compared to those that are resistant. We further hypothesize that since
tumor is continuously perfused by serum, serum protein profile can be used as a surrogate
marker of tumor protein profile. The primary objective of this study is to identify a serum
protein profile that predicts gemcitabine/carboplatin sensitivity or resistance in breast
cancer patients with prior exposure to anthracyclines and taxanes. Secondary objectives are
to establish the serum protein profile of breast cancer patients who have had prior exposure
to anthracyclines and taxanes, and to study the pharmacogenetics of gemcitabine toxicity by
correlating germline genotype of transporters and drug metabolizing enzymes with plasma and
intracellular gemcitabine pharmacokinetics.